NasdaqCM · Biotechnology

Ernexa Therapeutics (ERNA)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+517.3%

$30.00 average target

$4.86+0.24 (+5.3%)Latest market snapshot · Yahoo Finance

Market cap$5.7M

Cash$5.0M

Quarterly burn$2.3M

Pipeline assets1

Short float2.0%

Latest coverage

News & Press Releases

External sources

Jul 24, 2026

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer TherapiesGlobeNewswire

Jul 14, 2026

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026GlobeNewswire

Jul 15, 2026

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical EntryGlobeNewswire

Company profile

About Ernexa Therapeutics

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.